

2007

October

Mid-Atlantic Pharmacology Soc. Ann. Mtg.

Oct. 8, Philadelphia, PA
www.aspet.org/public/chapters/maps_chapter.htm

Univ. of Wisconsin Applied Drug Development 1: Preclinical & Drug Product Design Strategies

Oct. 8-12, Madison, WI
www.pharmacy.wisc.edu/esp/drugdevelopment

Int. Soc. for the Study of Xenobiotics 8th International ISSX Mtg.

Oct. 9-12, Sendai, Japan
www.issx.org

Cambridge Healthtech Inst. 2nd Ann. Drug Repositioning Summit

Oct. 10-11, Philadelphia, PA
www.healthtech.com

Roy. Pharmaceutical Soc. of Great Britain JPAG – Risk Assessment in Pharmaceut. Res., Develop. & Manufac.

Oct. 11, London, UK
www.rpsgb.org/pdfs/sciconf0710.pdf

Cambridge Healthtech Inst. Compound Profiling & Chemogenomic Approaches

Oct. 11-12, Philadelphia, PA
www.healthtech.com

SACNAS Nat. Conf.

Oct. 11-14, Kansas City, MO
www.sacnas.org

Southeastern Pharmacology Soc. Mtg.

Oct. 12-13, Augusta, GA
www.mcg.edu/som/phmtox/phix_sepsmeet.html

Inst. for Internat. Res. Establishing Proof of Concept in Phase I Trials

Oct. 16-18, Cambridge, MA
www.iirusa.com/phasel

Hereditary Breast &
Ovarian Cancer Foundation
2nd Int. Symp. on Hereditary
Breast & Ovarian Cancer
Oct. 17-19, Montreal, Canada
www.odon.ca/brca

Elsevier

17th Neuropharm. Conf. Cannabinoid Signaling in the Nervous System

Oct. 31 – Nov. 2, San Diego, CA
www.neuropharmacology-conference.elsevier.com

Nicotinic Acetylcholine Receptors as Therapeutic Targets (satellite to SfN Ann. Mtg.)

Oct. 31 – Nov. 2, San Diego, CA
www.cmpinc.net/nachr2007

November

Amer. Soc. of Cytopathology 55th Ann. Scientific Mtg.

Nov. 2-7, Houston, TX
www.cytopathology.org

Soc. for Neuroscience Ann. Mtg.

Nov. 3-7, San Diego, CA
www.sfn.org

Amer. Heart Assn. Scientific Sessions

Nov. 4-7, Orlando, FL
scientificsessions.americanheart.org

Ann. Biomed. Res. Conf. for Minority Students

Nov. 7-10, Austin, TX
www.abrcms.org

Soc. of Hospital Pharmacists of Australia 28th Federal Conf.

Nov. 8-11, Sydney, NSW, Australia
www.shpa.org.au

Asia & Oceania Fed. of Obstetrics & Gynecology

2nd Asia Pacific Congr. on Controversies
in Obstetrics, Gynecology & Infertility
Nov. 8-11, Shanghai, China
www.comtecmed.com/cogj/china

Cambridge Healthtech Inst. 2nd Ann. Post-Approval Drug Safety Strategies

Nov. 13-14, Philadelphia, PA

www.healthtech.com

NIH

5th Symp. on the Functional
Genomics of Critical Illness & Injury
Nov. 14-15, Bethesda, MD
www.strategicresults.com/fg5

Soc. of Pharmacovigilance (India) 7th Ann. Conf. on Pharmacovigilance & Drug Safety

Nov. 23-25, Jaipur, India
www.freewebs.com/sopi2007

Amer. Soc. of Lymphology 5th Ann. Conf.

Nov. 26-28, Kansas City, MO
www.lymphology.org

Nat. Prevention & Health Promotion Summit

Nov. 27-29, Washington, DC
www.healthierus.gov

Healthcare Education Services Ltd. Psychiatric Disorders – Treatment & Management

Nov. 28-29, Princeton, NJ
www.healthcare-ed.com

GTCBio Inc.

3rd Ann. Modern Drug Discovery & Development Summit

Nov. 28-30, San Francisco, CA
www.gtcbio.com

Int. Soc. of Cardiovascular Pharmacotherapy

14th Int. Cong. on Cardiovascular
Pharmacotherapy
Nov. 28 – Dec. 2, Antalya, Turkey
www.iscp2007.org

December

Amer. Soc. for Cell Biology 47th Ann. Mtg.

Dec. 1-5, Washington, DC
www.ascb.org

2008

January

Nat. Jewish Med. & Res. Ctr.
Proteomics & Genomics in the
World of Personalized Med.
Jan. 24-26, Denver, CO
www.njc.org/ProEd

February

Biophysical Society
52nd Ann. Mtg.
Feb. 2-6, Long Beach, CA
www.biophysics.org/meetings/2008

Keystone Symposia
1st Glimpses: Symp. on Drug Discovery
Feb. 3-8, Tahoe City, CA
www.keystonesymposia.org

Paragon Conventions
Int. Conf. on Fixed Combination in the
Treatment of Hypertension & Dyslipidemia
Feb. 7-10, Budapest, Hungary
[www.paragon-conventions.com/
category/fixe08](http://www.paragon-conventions.com/category/fixe08)

Amer. Heart Assn.
Int. Stroke Conf.
Feb. 20-22, New Orleans, LA
www.americanheart.org

April

Experimental Biology '08 &
ASPET's Centennial Celebration
Apr. 5-9, San Diego, CA
www.faseb.org/meetings

Amer. Assn. for Cancer Res.
Ann. Mtg.
Apr. 18-22, San Diego, CA
www.aacr.org

May

Roy. Pharmaceutical Soc. of Great Britain
10th Advanced Level Workshop on
Pharmacokinetic-Pharmacodynamic
Data Analysis
May 18-22, Cambridge, UK
www.rpsgb/worldofpharmacy/events

June

Org. for the Study of Sex Differences
2nd Ann. Mtg.
June 4-7, New Orleans, LA
www.ossdweb.org

Breast Cancer Foundation
5th World Conf. on Breast Cancer
June 4-8, Winnipeg, MB, Canada
www.wcbcf.ca

July

17th Int. Symp. on Microsomes
& Drug Oxidations
July 9-16, Saratoga Springs, NY
mdo2008.org

Fed. of European Neurosci. Socs.
6th Forum of European Neurosci.
Jul 12-16, Geneva, Switzerland
fens2008.neurosciences.asso.fr

Int. Academy of Cardiology
14th World Cong. on Heart Disease
July 16-29, Toronto, ON, Canada
www.cardiologyonline.com

IXth World Conf. on Clinical
Pharmacology & Therapeutics - CPT 2008
July 27 – Aug. 1, Quebec City, Canada
www.cpt2008.org

August

Amer. Psychological Assn.
116th Conv.
Aug. 14-17, Boston, MA
www.apa.org

September

ASBMR
30th Ann. Mtg.
Sept. 12-16, Montreal, Quebec, Canada
www.asbmr.org

October

2nd World Congress on Controversies in
Diabetes, Obesity and Hypertension
Oct. 30 – Nov. 2, Barcelona, Spain
www.codhy.com

November

Amer. Soc. of Cytopathology
56th Ann. Scientific Mtg.
Nov. 2-7, Orlando, FL
www.cytopathology.org

Ann. Biomed. Res. Conf.
for Minority Students
Nov. 5-8, Orlando, FL
www.abrcms.org

Soc. for Neuroscience
Ann. Mtg.
Nov. 15-19, Washington, DC
www.sfn.org

2009

April

Experimental Biology '09
April 18-22, New Orleans, LA
www.faseb.org/meetings

September

ASBMR
31st Ann. Mtg.
Sept. 11-15, Denver, CO
www.asbmr.org

October

Soc. for Neuroscience
Ann Mtg.
Oct. 24-28, Chicago, IL
www.sfn.org

Molecular Interventions Instructions to Authors

Revised September 28, 2007

Scope of Submitted Manuscripts

Papers published in **Molecular Interventions** are generally invited by the Editor after consideration of recommendations from the Editorial Advisory Board. Others who have an interest in writing for **Molecular Interventions** are encouraged to send proposals to the Editor. The proposal should include a detailed outline of the proposed article and a brief curriculum vitae. Articles in **Molecular Interventions** deal mainly with the current status of the subject under review. They are to be written clearly and concisely and should be intelligible to nonspecialists, with definitions of unfamiliar technical terms and explanations of difficult or controversial points included. At the same time, the review is to be sufficiently precise and detailed to command the attention and respect of experts in the field. Selective rather than exhaustive coverage of the literature is requested. Previous reviews of the subject and of related fields should be cited. Authors are asked to be critical of methods, results, and conclusions and to challenge accepted concepts where warranted. Conflicting points of view are to be presented objectively in good perspective. Deficiencies in the field may be pointed out and avenues for further work may be indicated. The usual length ranges between 8 and 12 printed pages, corresponding to about 24 to 36 manuscript pages. Diagrams, tables, and illustrations should be included to bring out new concepts and important relationships. The Art Director will work with the author to further develop graphics for the article.

Submission of Manuscripts

Submit three (3) collated hard copies of each manuscript (including illustrations) as well as an electronic version to

Dr. Harry B. Smith, Editor
Molecular Interventions
ASPET
9650 Rockville Pike
Bethesda, MD 20814-3995

telephone: 301-634-7790
fax: 301-634-7061
e-mail: hsmith@aspet.org

Diskettes produced on PC or Mac platforms are acceptable. Microsoft Word is preferred. Authors preparing diskettes on Macintosh computers should not use the Fast Save option. Other formats and files in ASCII can be used, but are not encouraged. Identify the diskette by providing the journal name, first author's name, manuscript title, name of computer file, type of hardware, operating system and version number, and software program and version number. Authors are encouraged to supply a digital copy of their illustrations. Image files should be submitted by e-mail or on zip disks (formatted for Mac or PC) or CDs; TIFF and EPS formats are strongly preferred. Illustrations created in Adobe Illustrator, Freehand, or Corel Draw should be saved in EPS format.

A completed copy of the **Molecular Interventions** Copyright Transfer form signed by all authors should be included with the manuscript at the time of submission (available from the online version of these *Instructions to Authors*). Submission of a manuscript amounts to assurance that it has received proper clearance from the author's company or institution, that it has not been copyrighted, published, or accepted for publication elsewhere, that it is not currently being considered for publication elsewhere, and that it will not be submitted elsewhere while under consideration by **Molecular Interventions**. The corresponding author is responsible for obtaining permission from the copyright owner to reproduce or modify figures and tables and to reproduce text (in whole or in part) from previous publications; permissions must allow electronic reproduction as well as print. A permissions request form is available online from the *Instructions to Authors*. The signed permissions must be submitted with the manuscript and be identified as to the relevant item in the manuscript (e.g., "permissions for Fig. 1"). In addition, a statement indicating that the material is being reprinted with permission must be included in the relevant figure legend or table footnote of the manuscript. Reprinted text must be enclosed in quotation marks, and the permission statement must be included as running text or indicated parenthetically.

Manuscripts must be in English, typewritten and double spaced throughout, including references, tables, and figure legends, using only one side of 8 1/2 by 11 inch (ca. 216 by 280 mm) paper, with at least 1 inch (25 mm) margins, and the copies must be collated. Pages should not be stapled. Three (3) sets of figures should be submitted, including one original set (see Figures). Three copies (3) of papers reporting any potentially overlapping earlier work (including relevant "in press" papers) must be included. Rejected manuscripts, figures, and original drawings will not be returned unless specifically requested at the time of submission.

Organization of the Manuscript

Manuscripts should contain the following sections in the order listed. Each section should begin on a new page and all pages should be numbered consecutively.

1. *Title page.* This should contain the complete title of the article, the names of all authors, and full contact information for corresponding author (address, phone, fax, e-mail). Financial support for the research should be indicated as an unnumbered footnote to the title and included with other footnotes on a separate page following the References section. A running title and at least five keywords should also be given.

2. *Abstract.* The abstract should be approximately 100 words, and should provide the context in which the topic of the article should be appreciated. The abstract should be intelligible to the general reader without reference to text. Reference citations are not permitted in abstracts, and nonstandard abbreviations should not be included.

3. *Body of manuscript.* It is highly recommended that the body be divided into conceptual sections, the first of which should be labeled INTRODUCTION and the last of which should be labeled CONCLUSIONS. Section headings should be given in all capital letters, subsection headings in standard title format, and sub-subsection headings in italics.

4. *Acknowledgments.* The Acknowledgments section is placed at the end of the text.

5. *References.* References are cited in the text by number. In the reference list, the references should be arranged in the order in which they are first cited in the text. The names of all authors should be given in the reference list. Abbreviations for journals should conform to the Medline abbreviation list, which is available from the online *Instructions to Authors*. References to personal communications, unpublished observations, and papers submitted for publication are given in parentheses at the appropriate location in the text, not in the list of references. Only papers that have been officially accepted for publication may be cited as "in press" in the reference list. The authors are responsible for the accuracy of the references. The format for journal article, chapter, and book references is as follows:

1. Griffiths, R.R., Bigelow, G.E., and Liebson, I.A. Human coffee drinking: Reinforcing and physical dependence producing effects of caffeine. *J. Pharmacol. Exp. Ther.* **239**, 416-425 (1997).

2. Chernow, B. and O'Brian, J.T. Overview of catecholamines in selected endocrine systems, in *Norepinephrine* (Ziegler, M.G. and Lake, C.R. eds) pp 439-449, Williams & Wilkins, Baltimore (1984).

3. Tallarida, R.J. and Murray, R.B. *Manual of Pharmacologic Calculations with Computer Programs.* Springer-Verlag, New York (1987).

6. *Tables.* Each table must be on a separate page. The tables are numbered consecutively with Arabic numerals, and designed to fit the column or page size of the journal. A brief descriptive title is provided at the top of each table. General statements about the table follow the title in paragraph form. Footnotes to tables are referenced by italicized, lower case, superscript letters (a, b, c, etc.) and defined beneath the table.

7. *Legends for figures.* Figures are numbered consecutively with Arabic numerals, with each one displayed on a separate page. Legends must provide sufficient explanation for the reader to understand the figure independent of the text.

8. *Figures.* Submit illustrations as glossy photographs, original India-ink drawings, or high-resolution laser printer output. Lettering on figures should be large enough to be legible after reduction to single-column width of 21 picas (about 3.5 inches or 9 cm). Letter typesizes after reduction should be 6-8 points. Do not use varying letter typesizes within a single figure; use the same size or similar sizes throughout the drawing. Figures should be ready, in all respects, for direct reproduction. All panels of a multipart figure should be provided on the same page. Although each of the manuscript copies should contain a complete set of figures, only the originals need be of the quality suitable for reproduction. In the case of halftones, three sets of photographs are required. If symbols are not explained on the face of the figure, only standard print characters may be used. The back of each figure should bear its number, the name of the first author, and the word TOP at the appropriate edge. Include figure titles in the legend and not on the figure itself. Photomicrographs and electron micrographs must be labeled with a magnification calibration in micrometers or Angstrom units. A statement concerning the magnification must appear in the figure legend.

9. *Author Photographs.* Supply a black-and-white or color glossy photograph of each author. Head size (top of head to bottom of chin) should be no smaller than 1.5 inches tall; also allow generous room on all sides for cropping. Write full name on back of photos; identify multiple authors as necessary.

10. *Additional images.* All authors are encouraged to submit images to be considered for use on the cover of **Molecular Interventions**. Cover images should be submitted as glossy (8x10) prints, transparencies or negatives, or as high-resolution digital files. Cover submissions should be accompanied by a 100-word description of the image. In addition, the title of each review article will be highlighted by an image selected by the editorial office; authors are encouraged to supply images with an appropriate caption for title treatment. Consult a recent issue of **Molecular Interventions** for examples.

Abbreviations, Drug Names, Gene Names, Etc

All abbreviations and technical nomenclature should be explained in parentheses upon their first use in the text. Do not abbreviate terms (other than standard abbreviations) that are used less than three times in the text. Generic drug names are used in text, tables, and figures. Trade names may be given in parentheses following the first text reference, but should not appear in titles, figures, or tables. Whereas trade names are capitalized, generic or chemical names are not.